Astrazeneca Plc · LSE:AZN
Astrazeneca — 9M and Q3 2026 Earnings Presentation
46 slides from Astrazeneca's earnings presentation, Oct 30, 2026
Slide 1: 9M and Q3 2026 Results
9M and Q3 2026 Results Conference call and webcast for investors and analysts 30 October 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Conference call agenda
9M and Q3 2026 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Haematology Dave Fredrickson Susan Galbraith EVP, Oncology Haematology Business EVP, Oncology Haematology R&D BioPharmaceuticals R
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 4
Slide 5: Strong 9M 2026 execution builds confidence in sustainable growth through the next decade
Strong 9M 2026 execution builds confidence in sustainable growth through the next decade +7% Total Revenue SUSTAINED COMMERCIAL +12% Total Revenue, ex. Farxiga and Brilinta1 MOMENTUM +14% Core EPS 12 positive Phase III programme readouts MEANINGFUL PROGRESS FOR 1st approval for 4 OUR PIPELINE2 new m
Slide 6: Growth driven by diverse therapy areas and global presence
Growth driven by diverse therapy areas and global presence +16% 9M 2026 | % Product Revenue by therapy area -5% ID: 735 Oncology CVRM R&I ID Other Rare Disease Strength across R&I: +10% 47% 18% 16% 2% 1% 16% therapy areas 7,268 +11% 9M 2026 | +6% Product Revenue ($m)1 CVRM: -15% 21,888 8,616 7,544 O
Slide 7: Twelve positive Phase III programme readouts YTD
Twelve positive Phase III programme readouts YTD OBERON efzimfotase CHESTNUT tozorakimab Imfinzi COPD TITANIA alfa MULBERRY locoregional HCC EMERALD-3 MIRANDA HPP HICKORY Ultomiris Imfinzi sone-ve I CAN VOLGA CLDN18.2+ 2L+ CLARITY-Gastric01 IgAN MIBC gastric cancer Tagrisso + Imfinzi Enhertu 1L urot
Slide 8: Enhancing the value of AstraZeneca's ADC portfolio through strategic collaboration with Summit
Enhancing the value of AstraZeneca’s ADC portfolio through strategic collaboration with Summit Datroway + Other AZ sone-ve + ivonescimab assets + ivonescimab ivonescimab Gastrointestinal cancers Breast and lung cancers Planned collaboration – Broadens and maximises AZ assets across key tumour types
Slide 9: Strategically investing to deliver growth beyond 2030
Strategically investing to deliver growth beyond 2030 Significant progress across our transformative technologies in 9M 2026 Weight ADCs and management Next-gen IO radio- Cell therapy T-cell engagers and CV risk bispecifics conjugates factors 1st Phase III data for Unprecedented OS benefit Ongoing s
Slide 10: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 10
Slide 11: 9M and Q3 2026 – Reported profit and loss
9M and Q3 2026 – Reported profit and loss 9M 2026 CER change % Total Q3 2026 CER change % Total $m % Revenue $m % Revenue - Product Sales 43,962 5 94 15,066 5 93 - Alliance Revenue 2,806 32 6 1,107 36 7 Product Revenue 46,768 6 100 16,173 7 100 - Collaboration Revenue 113 23 - 36 >3x - Total Revenue
Slide 12: 9M and Q3 2026 – Core profit and loss
9M and Q3 2026 – Core profit and loss 9M 2026 CER change % Total Q3 2026 CER change % Total $m % Revenue $m % Revenue - Product Sales 43,962 5 94 15,066 5 93 - Alliance Revenue 2,806 32 6 1,107 36 7 Product Revenue 46,768 6 100 16,173 7 100 - Collaboration Revenue 113 23 - 36 >3x - Total Revenue 46,
Slide 13: FY 2026 guidance reiterated
FY 2026 guidance reiterated Capital allocation priorities remain unchanged Net debt/EBITDA 1.2x FY 2026 Guidance (CER) $bn Total Anticipated to increase by a mid-to-high single-digit 5.0 1.8 Revenue percentage 10.9 4.3 2.3 Anticipated to increase by a 23.4 25.8 Core EPS low double-digit percentage N
Slide 14: Oncology
Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D 14
Slide 15: Oncology – 9M and Q3 2026
Oncology – 9M and Q3 2026 Total Revenue +16% in 9M 2026 and +17% in Q3, driven by continued global demand across key medicines Oncology Q3 2026: key dynamics 9M 2026 $21.9bn, +16% 8,500 • Tagrisso +12%, sustained 1L leadership with continued FLAURA2 uptake in 8,000 growing combo market 7,500 7,000 •
Slide 16: Oncology – reshaping practice across tumour types
Oncology – reshaping practice across tumour types Five presidential plenary sessions of AstraZeneca oncology data across WCLC and ESMO Tagrisso + Orpathys Enhertu Reinforcing Tagrisso SoC backbone in EGFRm NSCLC Expanding in HER2m NSCLC SAFFRON SANOVO DESTINY-Lung04 Imfinzi sone-ve Consolidating Ext
Slide 17: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D 17
Slide 18: BioPharmaceuticals – 9M and Q3 2026
BioPharmaceuticals – 9M and Q3 2026 Total Revenue -5% to $16.7bn; CVRM LoE impact partially offset by growth in R&I R&I CVRM Q3 2026: key dynamics 9M 2026 $7.3bn, +10% 9M 2026 $8.7bn, -14% 2,500 3,500 • Fasenra +14%, sustained IL-5 leadership in asthma, EGPA growth, ongoing China launch 3,000 2,000
Slide 19: BioPharmaceuticals – Key Phase III data support our growth ambitions
BioPharmaceuticals – Key Phase III data support our growth ambitions tozorakimab | Broad COPD efficacy reinforces Tezspire | Positive Phase III EoE data adds to $5bn+ PYR potential multi-blockbuster potential OBERON AND TITANIA PHASE III1 CROSSING PHASE III6 GOLD 4 mepolizumab2 69% GOLD stage GOLD 3
Slide 20: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 20
Slide 21: Rare Disease – 9M and Q3 2026
Rare Disease – 9M and Q3 2026 Total Revenue $7.5bn driven by key brands, advancing multiple launches across the portfolio Rare Disease Q3 2026: key dynamics Multiple launch opportunities 9M 2026 $7.5bn, +11% 3,000 C5 Franchise I CAN Approved in • Ultomiris +19%, growth across IgAN US, filed in JP 2,
Slide 22: Rare Disease – expanding our leadership with multiple blockbuster opportunities
Rare Disease – expanding our leadership with multiple blockbuster opportunities Ultomiris | Expanding into efzimfotase alfa | cliramitug | Differentiated IgAN Expansion beyond Strensiq TTR depleter MoA in ATTR-CM Ultomiris demonstrated consistent + Lower treatment burden patients progress efficacy a
Slide 23: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 23
Slide 24: Pipeline momentum continues through 2027
Pipeline momentum continues through 2027 Key readouts support NME growth outlook >15 other high-value readouts NME NRA PYR1 TROPION-Lung07 | Datroway Datroway AVANZAR H1 TROPION-Lung15 | Datroway ± Tagrisso $5bn+ 1L NSQ/NSQ TROP2+ NSCLC PACIFIC-9 | Imfinzi + oleclumab/monalizumab H1 reAZURE-PLUS | l
Slide 25: NMEs with pivotal data readouts before 2030 drive growth into and through the next decade
NMEs with pivotal data readouts before 2030 drive growth into and through the next decade >$5bn $3-5bn 1 sonesitatug vedotin2 AZD0120 volrustomig balcinrenone | zibotentan + cliramitug saruparib dapagliflozin surovatamig elecoglipron | AZD6234 | AZD9550 efzimfotase alfa rilvegostomig laroprovstat fr
Slide 26: Increasing confidence in Ambition 2030 and continued growth beyond
Increasing confidence in Ambition 2030 and continued growth beyond Revenue Delivery Commercial Scale Diverse Pipeline Investing for the Future $80bn 25+ 20+ 20 NMEs 2030 target on track1 potential blockbuster high value Phase III by 2030 – 14 launched 13% Total Revenue medicines by 2030 readouts thr
Slide 27: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Marc Dunoyer Susan Galbraith CHIEF EXECUTIVE OFFICER, EVP, ONCOLOGY ALEXION HAEMATOLOGY R&D Dave Fredrickson Sharon Barr EVP, ONCOLOGY EVP, BIOPHARMACEUTICALS HAEMATOLOGY BUSINESS R&D Ruud Dobber Iskra Reic EVP,
Slide 28: Appendix
Appendix
Slide 29: AstraZeneca P&L reference table
APPEN DI X | P&L definitions AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income ari
Slide 30: AstraZeneca P&L
APPEN DI X | P&L definitions AstraZeneca P&L 2026 P&L modelling considerations P&L line P&L Total Revenue • Expected to grow by a mid-to-high single-digit percentage at CER (guidance) Gross margin • Core gross margin expected to be stable to slightly better vs. 2025 R&D • Core R&D expense expected t
Slide 31: AstraZeneca in non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1st line 2nd line + Est. epi (G7, 2026) ~152K ~70K ~54K ~99K ~310K ~262K Imfinzi + Imjudo + CTx POSEIDON CRT → Imfinzi Datroway + IO ± platinum AVANZAR
Slide 32: AstraZeneca in EGFRm non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in EGFRm non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1st line 2nd line + Est. epi (G7, 2026) ~28K ~11K ~9K ~15K ~51K ~43K Tagrisso +/- CTx Datroway FLAURA, FLAURA2 TROPION-Lung05 Exon 19 deletions /
Slide 33: AstraZeneca in breast cancer
APPEN DI X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2026) 540k 135k 100k 70k 55k HER2-positive Enhertu → THP NST residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breas
Slide 34: AstraZeneca in gastric cancer
APPEN DI X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III/IVa 1st line 2nd line 3rd line Est. epi (G7, 2026) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu
Slide 35: AstraZeneca in bladder cancer
APPEN DI X | Oncology tumour maps AstraZeneca in bladder cancer High-risk NMIBC MIBC 1L mUC Est. epi (G7, 2026) 149k 81k 63k Neoadjuvant Imfinzi + EV ± Imjudo → adjuvant Imfinzi ± Imjudo VOLGA Neoadjuvant Imfinzi + CTx Imfinzi + BCG induction and maintenance → adjuvant Imfinzi Imfinzi + CTx ± Imjudo
Slide 36: AstraZeneca in asthma
APPEN DI X | R&I disease maps AstraZeneca in asthma Rescue / Reliever Symptom control Maintenance (Inhaled) Novel oral / inhaled / biologics (Inhaled) Est. epi (G8, 2026) ~54m treated ~25m ~3.6m EOS < 150 EOS 150–300 EOS > 300 (25%) (30%) (45%) Airsupra Mild (Step 1 + 2) Pulmicort Symbicort Airsupra
Slide 37: AstraZeneca in COPD
APPEN DI X | R&I disease maps AstraZeneca in COPD Exacerbation History Maintenance (Inhaled) Add on therapy Novel oral / inhaled / biologics (prior 12 mos) Est. epi (G8, 2026) ~40m treated ~4.6m EOS < 150 EOS 150–300 EOS > 300 (35%) (35%) (30%) Bevespi 0 exacerbations Breztri1 Breztri; THARROS Phase
Slide 38: Oncology: Tagrisso and Lynparza
APPEN DI X | Product Revenue Performance Oncology Tagrisso Lynparza 8% growth at CER to $5,862m in 9M 2026 2% decrease at CER to $2,421m in 9M 2026 1,000 2,500 900 800 2,000 700 Product Revenue ($m) Product Revenue ($m) 600 1,500 500 1,000 400 300 500 200 100 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1
Slide 39: Oncology: Imfinzi and Imjudo
APPEN DI X | Product Revenue Performance Oncology Imfinzi Imjudo 27% growth at CER to $5,538m in 9M 2026 4% growth at CER to $263m in 9M 2026 2,500 120 100 2,000 80 Product Revenue ($m) Product Revenue ($m) 1,500 60 1,000 40 500 20 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2024 2025
Slide 40: Oncology: Calquence and Enhertu
APPEN DI X | Product Revenue Performance Oncology Calquence Enhertu 16% growth at CER to $3,009m in 9M 2026 33% growth at CER to $2,688m in 9M 2026 1,200 1,200 1,000 1,000 800 800 Product Revenue ($m) Product Revenue ($m) 600 600 400 400 200 200 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 41: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Tezspire Saphnelo 13% growth at CER to $1,655m in 9M 2026 44% growth at CER to $1,123m in 9M 2026 27% growth at CER to $615m in 9M 2026 700 500 250 450 600 400 200 500 350 Product Revenue ($m) Product Reven
Slide 42: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Breztri Symbicort 16% growth at CER to $1,073m in 9M 2026 7% decrease at CER to $2,084m in 9M 2026 400 800 350 700 300 600 Product Revenue ($m) Product Revenue ($m) 250 500 200 400 150 300 100 200 50 100 0 0 Q3 Q4
Slide 43: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 15% decrease at CER to $5,603m in 9M 2026 62% decrease at CER to $261m in 9M 2026 23% growth at CER to $638m in 9M 2026 2,500 400 250 350 2,000 200 300 Product Revenue ($m) Produc
Slide 44: Rare Disease
APPEN DI X | Product Revenue Performance Rare Disease Ultomiris Strensiq Koselugo 16% growth at CER to $4,016m in 9M 2026 37% growth at CER to $1,641m in 9M 2026 15% growth at CER to $585m in 9M 2026 1,600 700 250 1,400 600 200 1,200 500 Product Revenue ($m) Product Revenue ($m) Product Revenue ($m)
Slide 45: Glossary
APPEN DI X | Glossary Glossary 1L, 2L, 3L first-, second-, third-line ERoW Esta blished Rest of World NMIBC non-muscle invasive bladder ca ncer 9M first nine m onths ESMO Europe an Society for Medical Oncology NMR+ normalised me mbrane ratio positive ACM all-cause mortality ESR1m estrogen receptor a
Slide 46: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis